Randomized Trial of Verubecestat for Mild-to-Moderate

New England Journal of Medicine
378, 1691-1703
DOI: 10.1056/nejmoa1706441

Citation Report

#	Article	IF	Citations
2	Somatic APP gene recombination in Alzheimerâ€™s disease and normal neurons. Nature, 2018, 563, 639-645.	13.7	179
3	Effects of a Dehydroevodiamine-Derivative on Synaptic Destabilization and Memory Impairment in the 5xFAD, Alzheimer's Disease Mouse Model. Frontiers in Behavioral Neuroscience, 2018, 12, 273.	1.0	22
4	Pathological Increases in Neuronal Hyperactivity in Selective Cholinergic and Noradrenergic Pathways May Limit the Efficacy of Amyloid-Î²-Based Interventions in Mild Cognitive Impairment and Alzheimerâ€™s Disease. Journal of Alzheimer's Disease Reports, 2018, 2, 165-167.	1.2	3
5	Pathogenic Feed-Forward Mechanisms in Alzheimerâ€™s and Parkinsonâ€™s Disease Converge on GSK-3. Brain Plasticity, 2018, 4, 151-167.	1.9	19
6	Discovery and Chemical Development of JNJ-50138803, a Clinical Candidate BACE1 Inhibitor. ACS Symposium Series, 2018, , 91-114.	0.5	0
7	Alzheimer's disease: The right drug, the right time. Science, 2018, 362, 1250-1251.	6.0	114
8	Cerebrospinal fluid neurogranin/Î²â€site APPâ€cleaving enzyme 1 predicts cognitive decline in preclinical Alzheimer's disease. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2018, 4, 617-627.	1.8	24
9	Discovery and Chemical Development of Verubecestat, a BACE1 Inhibitor for the Treatment of Alzheimerâ€™s Disease. ACS Symposium Series, 2018, , 53-89.	0.5	0
10	Can Arginase Inhibitors Be the Answer to Therapeutic Challenges in Alzheimer's Disease?. Neurotherapeutics, 2018, 15, 1032-1035.	2.1	8
11	Alzheimerâ€™s disease (AD) therapeutics â€“ 1: Repeated clinical failures continue to question the amyloid hypothesis of AD and the current understanding of AD causality. Biochemical Pharmacology, 2018, 158, 359-375.	2.0	59
12	Alzheimerâ€™s disease (AD) therapeutics â€“ 2: Beyond amyloid â€“ Re-defining AD and its causality to discover effective therapeutics. Biochemical Pharmacology, 2018, 158, 376-401.	2.0	24
13	BACE inhibitors in clinical development for the treatment of Alzheimerâ€™s disease. Expert Review of Neurotherapeutics, 2018, 18, 847-857.	1.4	66
14	Efficacy of chronic BACE1 inhibition in PS2APP mice depends on the regional AÎ² deposition rate and plaque burden at treatment initiation. Theranostics, 2018, 8, 4957-4968.	4.6	22
15	Pharmacokinetics in Rat of P8, a Peptide Drug Candidate for the Treatment of Alzheimerâ€™s Disease: Stability and Delivery to the Brain1. Journal of Alzheimer's Disease Reports, 2018, 2, 169-179.	1.2	5
16	Questions concerning the role of amyloid-Î² in the definition, aetiology and diagnosis of Alzheimerâ€™s disease. Acta Neuropathologica, 2018, 136, 663-689.	3.9	151
17	A promising, novel, and unique <scp>BACE</scp> 1 inhibitor emerges in the quest to prevent Alzheimer's disease. EMBO Molecular Medicine, 2018, 10, .	3.3	28
18	Insulin Resistance in Alzheimer's Disease. Frontiers in Neuroscience, 2018, 12, 830.	1.4	147
19	The <scp>BACE</scp> â€1 inhibitor <scp>CNP</scp> 520 for prevention trials in Alzheimer's disease. EMBO Molecular Medicine, 2018, 10, .	3.3	112

#	Article	IF	Citations
20	Axonal organization defects in the hippocampus of adult conditional BACE1 knockout mice. Science Translational Medicine, 2018, 10, .	5.8	66
21	Consequences of Pharmacological BACE Inhibition on Synaptic Structure and Function. Biological Psychiatry, 2018, 84, 478-487.	0.7	41
22	Sex differences in Alzheimer disease â€" the gateway to precision medicine. Nature Reviews Neurology, 2018, 14, 457-469.	4.9	573
23	BACE1 Inhibitor MK-8931 Alters Formation but Not Stability of Dendritic Spines. Frontiers in Aging Neuroscience, 2018, 10, 229.	1.7	27
24	Pharmacodynamics of atabecestat (JNJ-54861911), an oral BACE1 inhibitor in patients with early Alzheimerâ€™s disease: randomized, double-blind, placebo-controlled study. Alzheimer's Research and Therapy, 2018, 10, 85.	3.0	69
25	Ocular amyloid imaging at the crossroad of Alzheimerâ€™s disease and age-related macular degeneration: implications for diagnosis and therapy. Journal of Neurology, 2019, 266, 1566-1577.	1.8	23
26	Effect and Safety of Huannao Yicong Formula (è¿˜è„‘ç›Šèªæ–¹) in Patients with Mild-to-Moderate Alzheimerâ€™s Disease: A Randomized, Double-Blinded, Donepezil-Controlled Trial. Chinese Journal of Integrative Medicine, 2019, 25, 574-581.	0.7	16
27	Neuro-regeneration Therapeutic for Alzheimerâ€™s Dementia: Perspectives on Neurotrophic Activity. Trends in Pharmacological Sciences, 2019, 40, 655-668.	4.0	21
28	EDITORIAL: FAILURE AFTER FAILURE. WHAT NEXT IN AD DRUG DEVELOPMENT?. journal of prevention of Alzheimer's disease, The, 2019, 6, 1-1.	1.5	18
29	Further analyses of the safety of verubecestat in the phase 3 EPOCH trial of mild-to-moderate Alzheimerâ€™s disease. Alzheimer's Research and Therapy, 2019, 11, 68.	3.0	44
30	Multiple BACE1 inhibitors abnormally increase the BACE1 protein level in neurons by prolonging its halfâ€life. Alzheimer's and Dementia, 2019, 15, 1183-1194.	0.4	17
31	Current and emerging avenues for Alzheimer's disease drug targets. Journal of Internal Medicine, 2019, 286, 398-437.	2.7	102
32	Alzheimer's disease drug development pipeline: 2019. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2019, 5, 272-293.	1.8	546
33	A Rationally Designed Humanized Antibody Selective for Amyloid Beta Oligomers in Alzheimerâ€™s Disease. Scientific Reports, 2019, 9, 9870.	1.6	35
34	Sleep and Î²-Amyloid Deposition in Alzheimer Disease: Insights on Mechanisms and Possible Innovative Treatments. Frontiers in Pharmacology, 2019, 10, 695.	1.6	85
35	Early AÎ² reduction prevents progression of cerebral amyloid angiopathy. Annals of Neurology, 2019, 86, 561-571.	2.8	18
36	Kihito, a Traditional Japanese Kampo Medicine, Improves Cognitive Function in Alzheimerâ€™s Disease Patients. Evidence-based Complementary and Alternative Medicine, 2019, 2019, 1-7.	0.5	18
37	Canine Cognitive Dysfunction and Alzheimerâ€™s Disease â€“ Two Facets of the Same Disease?. Frontiers in Neuroscience, 2019, 13, 604.	1.4	56

#	Article	IF	Citations
38	Brain AÎ² load association and sexual dimorphism of plasma BACE1 concentrations in cognitively normal individuals at risk for AD. Alzheimer's and Dementia, 2019, 15, 1274-1285.	0.4	25
39	Hippocampal subfield volumes and pre-clinical Alzheimerâ€™s disease in 408 cognitively normal adults born in 1946. PLoS ONE, 2019, 14, e0224030.	1.1	26
40	Clinical Characteristics in Subjective Cognitive Decline with and without Worry: Baseline Investigation of the SILCODE Study. Journal of Alzheimer's Disease, 2019, 72, 443-454.	1.2	25
41	Applications of Quantitative Systems Pharmacology in Modelâ€Informed Drug Discovery: Perspective on Impact and Opportunities. CPT: Pharmacometrics and Systems Pharmacology, 2019, 8, 777-791.	1.3	45
42	Investigational BACE inhibitors for the treatment of Alzheimerâ€™s disease. Expert Opinion on Investigational Drugs, 2019, 28, 967-975.	1.9	94
43	Tau deletion reduces plaqueâ€associated <scp>BACE</scp> 1 accumulation and decelerates plaque formation in a mouse model of Alzheimer's disease. EMBO Journal, 2019, 38, e102345.	3.5	24
44	Current Landscape of Late-Phase Clinical Trials for Alzheimerâ€™s Disease: Comparing Regional Variation Between Subjects in Japan and North America. Pharmaceutical Medicine, 2019, 33, 511-518.	1.0	2
45	Randomized controlled trial of TDCS on cognition in 201 seniors with mild neurocognitive disorder. Annals of Clinical and Translational Neurology, 2019, 6, 1938-1948.	1.7	43
46	Trifluoromethyl Dihydrothiazineâ€Based Î²â€Secretase (BACE1) Inhibitors with Robust Central Î²â€Amyloid Reduction and Minimal Covalent Binding Burden. ChemMedChem, 2019, 14, 1894-1910.	1.6	8
47	Emerging Approaches to Investigate the Influence of Transition Metals in the Proteinopathies. Cells, 2019, 8, 1231.	1.8	19
48	History and progress of hypotheses and clinical trials for Alzheimerâ€™s disease. Signal Transduction and Targeted Therapy, 2019, 4, 29.	7.1	370
49	Safety, Tolerability, Pharmacokinetics, and Pharmacodynamic Effects of PF-06751979, a Potent and Selective Oral BACE1 Inhibitor: Results from Phase I Studies in Healthy Adults and Healthy Older Subjects. Journal of Alzheimer's Disease, 2019, 71, 581-595.	1.2	16
51	Lessons that can be learnt from the failure of verubecestat in Alzheimerâ€™s disease. Expert Opinion on Pharmacotherapy, 2019, 20, 2095-2099.	0.9	13
52	Development of new treatments for Alzheimerâ€™s disease based on the modulation of translocator protein (TSPO). Ageing Research Reviews, 2019, 54, 100943.	5.0	10
53	Isorhynchophylline ameliorates cognitive impairment via modulating amyloid pathology, tau hyperphosphorylation and neuroinflammation: Studies in a transgenic mouse model of Alzheimerâ€™s disease. Brain, Behavior, and Immunity, 2019, 82, 264-278.	2.0	37
54	Combinatorial Treatment Using Umbilical Cord Perivascular Cells and AÎ² Clearance Rescues Vascular Function Following Transient Hypertension in a Rat Model of Alzheimer Disease. Hypertension, 2019, 74, 1041-1051.	1.3	11
55	Refining the understanding of typical Alzheimer disease. Nature Reviews Neurology, 2019, 15, 623-624.	4.9	3
56	Chinese herbal medicine Qinggongshoutao for the treatment of amnestic mild cognitive impairment: A 52â€week randomized controlled trial. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2019, 5, 441-449.	1.8	14

#	Article	IF	Citations
57	Do anti-amyloid-Î² drugs affect neuropsychiatric status in Alzheimerâ€™s disease patients?. Ageing Research Reviews, 2019, 55, 100948.	5.0	24
58	Spore powder of Ganoderma lucidum for Alzheimer's disease. Medicine (United States), 2019, 98, e14382.	0.4	9
59	Risk Factors for Alzheimerâ€™s Disease: Focus on Stress. Frontiers in Pharmacology, 2019, 10, 976.	1.6	20
60	Alzheimer Disease: An Update on Pathobiology and Treatment Strategies. Cell, 2019, 179, 312-339.	13.5	1,675
61	Design and development of molecular hybrids of 2-pyridylpiperazine and 5-phenyl-1,3,4-oxadiazoles as potential multifunctional agents to treat Alzheimer's disease. European Journal of Medicinal Chemistry, 2019, 183, 111707.	2.6	46
62	New Semi-Automated Computer-Based System for Assessing the Purge of Mutagenic Impurities. Organic Process Research and Development, 2019, 23, 2470-2481.	1.3	16
63	Current and Emerging Pharmacological Targets for the Treatment of Alzheimerâ€™s Disease. Journal of Alzheimer's Disease, 2019, 72, S145-S176.	1.2	26
64	Discovery of an Extremely Potent Thiazine-Based Î²-Secretase Inhibitor with Reduced Cardiovascular and Liver Toxicity at a Low Projected Human Dose. Journal of Medicinal Chemistry, 2019, 62, 9331-9337.	2.9	7
65	Treatment Combinations for Alzheimerâ€™s Disease: Current and Future Pharmacotherapy Options. Journal of Alzheimer's Disease, 2019, 67, 779-794.	1.2	336
66	Design, synthesis, and biological evaluation of 4â€aminopyrimidine or 4,6â€diaminopyrimidine derivatives as beta amyloid cleaving enzymeâ€1 inhibitors. Chemical Biology and Drug Design, 2019, 93, 926-933.	1.5	7
67	Lack of Î²-amyloid cleaving enzyme-1 (BACE1) impairs long-term synaptic plasticity but enhances granule cell excitability and oscillatory activity in the dentate gyrus in vivo. Brain Structure and Function, 2019, 224, 1279-1290.	1.2	9
68	Human iPS Cell-Derived Patient Tissues and 3D Cell Culture Part 2: Spheroids, Organoids, and Disease Modeling. SLAS Technology, 2019, 24, 18-27.	1.0	27
69	A short perspective on the long road to effective treatments for Alzheimer's disease. British Journal of Pharmacology, 2019, 176, 3636-3648.	2.7	17
70	The Î²â€secretase (BACE) inhibitor NBâ€360 in preclinical models: From amyloidâ€Î² reduction to downstream diseaseâ€relevant effects. British Journal of Pharmacology, 2019, 176, 3435-3446.	2.7	17
71	Sex differences in Alzheimerâ€™s disease: Understanding the molecular impact. Brain Research, 2019, 1719, 194-207.	1.1	53
72	Do BACE inhibitor failures in Alzheimer patients challenge the amyloid hypothesis of the disease?. Expert Review of Neurotherapeutics, 2019, 19, 599-602.	1.4	32
73	Neurotoxic astrocytes express the d-serine synthesizing enzyme, serine racemase, in Alzheimer's disease. Neurobiology of Disease, 2019, 130, 104511.	2.1	49
74	Plant-based vaccines for Alzheimerâ€™s disease. Proceedings of the Japan Academy Series B: Physical and Biological Sciences, 2019, 95, 290-294.	1.6	8

#	Article	IF	Citations
75	The Alzheimer's Prevention Initiative Generation Program: Study design of two randomized controlled trials for individuals at risk for clinical onset of Alzheimer's disease. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2019, 5, 216-227.	1.8	80
76	Safety, Tolerability, and Pharmacokinetics of the Î²â€Site Amyloid Precursor Proteinâ€Cleaving Enzyme 1 Inhibitor Verubecestat (<scp>MK</scp>â€8931) in Healthy Elderly Male and Female Subjects. Clinical and Translational Science, 2019, 12, 545-555.	1.5	14
77	Neuroprotection in Alzheimer Disease. Springer Protocols, 2019, , 465-585.	0.1	1
78	Î²-secretase inhibitors for Alzheimer's disease: heading in the wrong direction?. Lancet Neurology, The, 2019, 18, 624-626.	4.9	17
79	Combining hippocampal volume metrics to better understand Alzheimerâ€™s disease progression in at-risk individuals. Scientific Reports, 2019, 9, 7499.	1.6	16
80	Identification of Temporal Characteristic Networks of Peripheral Blood Changes in Alzheimerâ€™s Disease Based on Weighted Gene Co-expression Network Analysis. Frontiers in Aging Neuroscience, 2019, 11, 83.	1.7	25
81	A metabolic perspective of late onset Alzheimerâ€™s disease. Pharmacological Research, 2019, 145, 104255.	3.1	19
82	ADVANCING ALZHEIMERâ€™S DISEASE TREATMENT: LESSONS FROM CTAD 2018. journal of prevention of Alzheimer's disease, The, 2019, 6, 1-6.	1.5	6
83	COMMENTARY: COMBINATION THERAPY FOR ALZHEIMERâ€™S DISEASE â€“ THE NEXT STEP. journal of prevention of Alzheimer's disease, The, 2019, 6, 1-1.	1.5	0
84	Altered microRNAs related to synaptic function as potential plasma biomarkers for Alzheimerâ€™s disease. Alzheimer's Research and Therapy, 2019, 11, 46.	3.0	83
85	Bispecific Antibody Fragment Targeting APP and Inducing Î±-Site Cleavage Restores Neuronal Health in an Alzheimerâ€™s Mouse Model. Molecular Neurobiology, 2019, 56, 7420-7432.	1.9	9
86	Excitatory-inhibitory imbalance in Alzheimer's disease and therapeutic significance. Neurobiology of Disease, 2019, 127, 605-615.	2.1	79
87	Disease Modification in Alzheimerâ€™s Disease: Current Thinking. Therapeutic Innovation and Regulatory Science, 2019, , 216847901984189.	0.8	1
88	Structure-Based Design of Selective Î²-Site Amyloid Precursor Protein Cleaving Enzyme 1 (BACE1) Inhibitors: Targeting the Flap to Gain Selectivity over BACE2. Journal of Medicinal Chemistry, 2019, 62, 5080-5095.	2.9	29
89	Harnessing Immunoproteostasis to Treat Neurodegenerative Disorders. Neuron, 2019, 101, 1003-1015.	3.8	29
90	A Close Look at BACE1 Inhibitors for Alzheimerâ€™s Disease Treatment. CNS Drugs, 2019, 33, 251-263.	2.7	115
91	New flavonoid â€“ N,N-dibenzyl(N-methyl)amine hybrids: Multi-target-directed agents for AlzheimerÂ´s disease endowed with neurogenic properties. Journal of Enzyme Inhibition and Medicinal Chemistry, 2019, 34, 712-727.	2.5	27
92	Why Amyloid Is Still a Target for Alzheimer Disease Clinical Trials. Journal of the American Geriatrics Society, 2019, 67, 845-847.	1.3	4

#	Article	IF	Citations
93	Lowering of Amyloid-Beta by Î²-Secretase Inhibitors â€" Some Informative Failures. New England Journal of Medicine, 2019, 380, 1476-1478.	13.9	56
94	Randomized Trial of Verubecestat for Prodromal Alzheimerâ€™s Disease. New England Journal of Medicine, 2019, 380, 1408-1420.	13.9	397
95	Carotid artery wave intensity in mid- to late-life predicts cognitive decline: the Whitehall II study. European Heart Journal, 2019, 40, 2300-2309.	1.0	57
96	Sensitivity of a Preclinical Alzheimerâ€™s Cognitive Composite (PACC) to amyloid Î² load in preclinical Alzheimerâ€™s disease. Journal of Clinical and Experimental Neuropsychology, 2019, 41, 591-600.	0.8	18
97	Current and Future Treatments in Alzheimer's Disease. Seminars in Neurology, 2019, 39, 227-240.	0.5	161
98	Autophagy Activator Drugs: A New Opportunity in Neuroprotection from Misfolded Protein Toxicity. International Journal of Molecular Sciences, 2019, 20, 901.	1.8	81
99	Increased Secondary Nucleation Underlies Accelerated Aggregation of the Four-Residue N-Terminally Truncated AÎ²42 Species AÎ²5â€"42. ACS Chemical Neuroscience, 2019, 10, 2374-2384.	1.7	16
100	Multitarget-directed ligands for neurodegenerative diseases: real opportunity or blurry mirage?. Future Medicinal Chemistry, 2019, 11, 261-263.	1.1	13
101	Early Diagnosis of Alzheimerâ€™s Disease. , 2019, , 7-12.		0
102	Present Algorithms and Future Treatments for Alzheimerâ€™s Disease. Journal of Alzheimer's Disease, 2019, 67, 1157-1171.	1.2	76
103	Dynamic Docking of a Medium-Sized Molecule to Its Receptor by Multicanonical MD Simulations. Journal of Physical Chemistry B, 2019, 123, 2479-2490.	1.2	22
104	Identification of a Simple and Novel Cut-Point Based Cerebrospinal Fluid and MRI Signature for Predicting Alzheimerâ€™s Disease Progression that Reinforces the 2018 NIA-AA Research Framework. Journal of Alzheimer's Disease, 2019, 68, 537-550.	1.2	11
105	The Role of Biomarkers in Alzheimerâ€™s Disease Drug Development. Advances in Experimental Medicine and Biology, 2019, 1118, 29-61.	0.8	84
106	Curcumin Alleviates Î² Amyloid-Induced Neurotoxicity in HT22 CellsÂvia Upregulating SOD2. Journal of Molecular Neuroscience, 2019, 67, 540-549.	1.1	17
107	Arousal and the Alzheimer disease. , 2019, , 131-141.		1
108	Diagnosis and Treatment of Alzheimerâ€™s Disease in Elderly and Senile Age. Advances in Gerontology, 2019, 9, 439-446.	0.1	0
109	BACE1 partial deletion induces synaptic plasticity deficit in adult mice. Scientific Reports, 2019, 9, 19877.	1.6	25
110	Preventing Cognitive Decline and Dementia. , 2019, , 291-306.		2

#	Article	IF	Citations
111	Gantenerumab reduces amyloid-Î² plaques in patients with prodromal to moderate Alzheimerâ€™s disease: a PET substudy interim analysis. Alzheimer's Research and Therapy, 2019, 11, 101.	3.0	131
112	Alzheimerâ€™s Disease Clinical Trials: Moving Toward Successful Prevention. CNS Drugs, 2019, 33, 99-106.	2.7	33
113	A critical appraisal of amyloid-Î²-targeting therapies for AlzheimerÂdisease. Nature Reviews Neurology, 2019, 15, 73-88.	4.9	666
114	Are antibodies directed against amyloid-Î² (AÎ²) oligomers the last call for the AÎ² hypothesis of Alzheimer's disease?. Immunotherapy, 2019, 11, 3-6.	1.0	50
115	New evolutions in the BACE1 inhibitor field from 2014 to 2018. Bioorganic and Medicinal Chemistry Letters, 2019, 29, 761-777.	1.0	57
116	Implications of Successful Symptomatic Treatment in Parkinsonâ€™s Disease for Therapeutic Strategies of Alzheimerâ€™s Disease. ACS Chemical Neuroscience, 2019, 10, 922-930.	1.7	6
117	New approaches for the treatment of Alzheimerâ€™s disease. Bioorganic and Medicinal Chemistry Letters, 2019, 29, 125-133.	1.0	111
118	Treating Alzheimer's disease by targeting iron. British Journal of Pharmacology, 2019, 176, 3622-3635.	2.7	71
119	Bad news and good news in AD, and how to reconcile them. Nature Reviews Neurology, 2019, 15, 61-62.	4.9	35
120	Amyloidâ€Î² immunotherapy for alzheimer disease: Is it now a long shot?. Annals of Neurology, 2019, 85, 303-315.	2.8	126
121	3K3A-activated protein C blocks amyloidogenic BACE1 pathway and improves functional outcome in mice. Journal of Experimental Medicine, 2019, 216, 279-293.	4.2	55
122	A Proposed Roadmap for Parkinsonâ€™s Disease Proof of Concept Clinical Trials Investigating Compounds Targeting Alpha-Synuclein. Journal of Parkinson's Disease, 2019, 9, 31-61.	1.5	45
123	Pathological Changes of Tau Related to Alzheimerâ€™s Disease. ACS Chemical Neuroscience, 2019, 10, 931-944.	1.7	54
124	Current viral-mediated gene transfer research for treatment of Alzheimerâ€™s disease. Biotechnology and Genetic Engineering Reviews, 2019, 35, 26-45.	2.4	14
125	Inhibitors of NF-ÎºB and P2X7/NLRP3/Caspase 1 pathway in microglia: Novel therapeutic opportunities in neuroinflammation induced early-stage Alzheimerâ€™s disease. Journal of Neuroimmunology, 2019, 326, 62-74.	1.1	170
126	Improvements of symptoms of Alzheimer`s disease by inhibition of the angiotensin system. Pharmacological Research, 2020, 154, 104230.	3.1	37
127	Discovery of AM-6494: A Potent and Orally Efficacious Î²-Site Amyloid Precursor Protein Cleaving Enzyme 1 (BACE1) Inhibitor with in Vivo Selectivity over BACE2. Journal of Medicinal Chemistry, 2020, 63, 2263-2281.	2.9	25
128	Quantification and pharmacokinetic property of verubecestat an BACE1 inhibitor in rat plasma. Biomedical Chromatography, 2020, 34, e4715.	0.8	2

#	Article	IF	Citations
129	Preparation and in vitro evaluation of multi-target-directed selenium-chondroitin sulfate nanoparticles in protecting against the Alzheimer's disease. International Journal of Biological Macromolecules, 2020, 142, 265-276.	3.6	41
130	Reduction of blood glucose by plant extracts and their use in the treatment of diabetes mellitus; discrepancies in effectiveness between animal and human studies. Journal of Ethnopharmacology, 2020, 247, 112264.	2.0	34
131	A combinational treatment of carotenoids decreases AÎ² secretion in human neurons via Î²-secretase inhibition. Neuroscience Research, 2020, 158, 47-55.	1.0	7
132	BACE1 inhibitors: Current status and future directions in treating Alzheimer's disease. Medicinal Research Reviews, 2020, 40, 339-384.	5.0	177
133	Aspirin and its pleiotropic application. European Journal of Pharmacology, 2020, 866, 172762.	1.7	64
134	A 20-Year Journey from Axonal Injury to Neurodegenerative Diseases and the Prospect of Immunotherapy for Combating Alzheimerâ€™s Disease. Journal of Immunology, 2020, 204, 243-250.	0.4	26
135	Progress and perspectives of brain-targeting lipid-based nanosystems via the nasal route in Alzheimerâ€™s disease. European Journal of Pharmaceutics and Biopharmaceutics, 2020, 148, 38-53.	2.0	64
136	Î´-secretase in neurodegenerative diseases: mechanisms, regulators and therapeutic opportunities. Translational Neurodegeneration, 2020, 9, 1.	3.6	60
137	Endosomal dysfunction impacts extracellular vesicle release: Central role in AÎ² pathology. Ageing Research Reviews, 2020, 58, 101006.	5.0	29
138	Mouse brain proteomics establishes MDGA1 and CACHD1 as in vivo substrates of the Alzheimer protease BACE1. FASEB Journal, 2020, 34, 2465-2482.	0.2	16
139	Delivery of exogenous proteins by mesenchymal stem cells attenuates early memory deficits in a murine model of Alzheimer's disease. Neurobiology of Aging, 2020, 86, 81-91.	1.5	18
140	Sequential parallel comparison design with two coprimary endpoints. Pharmaceutical Statistics, 2020, 19, 243-254.	0.7	2
141	Efficacy and Safety of Lanabecestat for Treatment of Early and Mild Alzheimer Disease. JAMA Neurology, 2020, 77, 199.	4.5	123
142	Smart treatment strategies for alleviating tauopathy and neuroinflammation to improve clinical outcome in Alzheimer's disease. Drug Discovery Today, 2020, 25, 2110-2129.	3.2	12
143	Sowing the Seeds of Discovery: Tau-Propagation Models of Alzheimerâ€™s Disease. ACS Chemical Neuroscience, 2020, 11, 3499-3509.	1.7	7
144	Anti-AÎ² agents for mild to moderate Alzheimer's disease: systematic review and meta-analysis. Journal of Neurology, Neurosurgery and Psychiatry, 2020, 91, 1316-1324.	0.9	24
145	Alzheimer's disease: Recent treatment strategies. European Journal of Pharmacology, 2020, 887, 173554.	1.7	300
146	An Immunomodulatory Therapeutic Vaccine Targeting Oligomeric Amyloid-Î². Journal of Alzheimer's Disease, 2020, 77, 1639-1653.	1.2	8

#	Article	IF	Citations
147	Cognitive outcomes in trials of two BACE inhibitors in Alzheimer's disease. Alzheimer's and Dementia, 2020, 16, 1483-1492.	0.4	46
148	Rational design and biological evaluation of a new class of thiazolopyridyl tetrahydroacridines as cholinesterase and GSK-3 dual inhibitors for Alzheimerâ€™s disease. European Journal of Medicinal Chemistry, 2020, 207, 112751.	2.6	15
149	Discontinued disease-modifying therapies for Alzheimerâ€™s disease: status and future perspectives. Expert Opinion on Investigational Drugs, 2020, 29, 919-933.	1.9	22
150	Alzheimer's disease drug development pipeline: 2020. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2020, 6, e12050.	1.8	353
151	Gga3 deletion and a GGA3 rare variant associated with late onset Alzheimerâ€™s disease trigger BACE1 accumulation in axonal swellings. Science Translational Medicine, 2020, 12, .	5.8	11
152	Current Progress and Future Directions for Tau-Based Fluid Biomarker Diagnostics in Alzheimerâ€™s Disease. International Journal of Molecular Sciences, 2020, 21, 8673.	1.8	8
153	BACE inhibition causes rapid, regional, and non-progressive volume reduction in Alzheimerâ€™s disease brain. Brain, 2020, 143, 3816-3826.	3.7	41
155	Neuronal deficiency of p38Î±â€MAPK ameliorates symptoms and pathology of APP or Tauâ€transgenic Alzheimerâ€™s mouse models. FASEB Journal, 2020, 34, 9628-9649.	0.2	19
156	Dementia prevention, intervention, and care: 2020 report of the Lancet Commission. Lancet, The, 2020, 396, 413-446.	6.3	4,658
157	An update on potential links between type 2 diabetes mellitus and Alzheimerâ€™s disease. Molecular Biology Reports, 2020, 47, 6347-6356.	1.0	28
158	A randomized, controlled clinical trial of plasma exchange with albumin replacement for Alzheimer's disease: Primary results of the AMBAR Study. Alzheimer's and Dementia, 2020, 16, 1412-1425.	0.4	82
159	<scp>AP</scp> â€2 reduces amyloidogenesis by promoting <scp>BACE</scp> 1 trafficking and degradation in neurons. EMBO Reports, 2020, 21, e47954.	2.0	36
160	Targeting Amyloidogenic Processing of APP in Alzheimerâ€™s Disease. Frontiers in Molecular Neuroscience, 2020, 13, 137.	1.4	73
161	Effect of Rotigotine vs Placebo on Cognitive Functions Among Patients With Mild to Moderate Alzheimer Disease. JAMA Network Open, 2020, 3, e2010372.	2.8	34
162	Behavioral and neural network abnormalities in human APP transgenic mice resemble those of App knock-in mice and are modulated by familial Alzheimerâ€™s disease mutations but not by inhibition of BACE1. Molecular Neurodegeneration, 2020, 15, 53.	4.4	44
163	Current Biomarkers for Alzheimerâ€™s Disease: From CSF to Blood. Journal of Personalized Medicine, 2020, 10, 85.	1.1	42
164	Revisiting the Amyloid Cascade Hypothesis: From Anti-AÎ² Therapeutics to Auspicious New Ways for Alzheimerâ€™s Disease. International Journal of Molecular Sciences, 2020, 21, 5858.	1.8	79
165	Therapeutic Targeting Strategies for Early- to Late-Staged Alzheimerâ€™s Disease. International Journal of Molecular Sciences, 2020, 21, 9591.	1.8	24

#	Article	IF	Citations
166	The Role of Chronic Inflammatory Bone and Joint Disorders in the Pathogenesis and Progression of Alzheimer's Disease. Frontiers in Aging Neuroscience, 2020, 12, 583884.	1.7	14
167	Modulation of Brain Hyperexcitability: Potential New Therapeutic Approaches in Alzheimerâ€™s Disease. International Journal of Molecular Sciences, 2020, 21, 9318.	1.8	54
168	Mosaic Somatic Gene Recombination as a Potentially Unifying Hypothesis for Alzheimerâ€™s Disease. Frontiers in Genetics, 2020, 11, 390.	1.1	14
169	Long-term safety and tolerability of atabecestat (JNJ-54861911), an oral BACE1 inhibitor, in early Alzheimerâ€™s disease spectrum patients: a randomized, double-blind, placebo-controlled study and a two-period extension study. Alzheimer's Research and Therapy, 2020, 12, 58.	3.0	56
170	The Role of P2X7 Receptor in Alzheimerâ€™s Disease. Frontiers in Molecular Neuroscience, 2020, 13, 94.	1.4	44
171	Alzheimerâ€™s Disease â€œNon-amyloidogenicâ€•p3 Peptide Revisited: A Case for Amyloid-Î±. ACS Chemical Neuroscience, 2020, 11, 1539-1544.	1.7	23
172	Revisiting the role of brain and peripheral AÎ² in the pathogenesis of Alzheimer's disease. Journal of the Neurological Sciences, 2020, 416, 116974.	0.3	48
173	Quantitative Analysis of 7 Compounds in Diospyros lotus Leaf Extract and Its Biological Effects on Neuroprotection and Antineuroinflammation. Natural Product Communications, 2020, 15, 1934578X2092485.	0.2	2
174	Is the p3 Peptide (AÎ²17-40, AÎ²17-42) Relevant to the Pathology of Alzheimerâ€™s Disease?1. Journal of Alzheimer's Disease, 2020, 74, 43-53.	1.2	14
175	A Novel Compound YS-5-23 Exhibits Neuroprotective Effect by Reducing Î²-Site Amyloid Precursor Protein Cleaving Enzyme 1â€™s Expression and H2O2-Induced Cytotoxicity in SH-SY5Y Cells. Neurochemical Research, 2020, 45, 2113-2127.	1.6	2
176	Amyloid-Î²42/40 ratio drives tau pathology in 3D human neural cell culture models of Alzheimerâ€™s disease. Nature Communications, 2020, 11, 1377.	5.8	88
177	Repurposing Clinical Drugs as AdoMetDC Inhibitors Using the SCAR Strategy. Frontiers in Pharmacology, 2020, 11, 248.	1.6	12
178	Discovery of small molecules for the treatment of Alzheimerâ€™s disease. , 2020, , 289-322.		1
179	Detecting earlier stages of amyloid deposition using PET in cognitively normal elderly adults. Neurology, 2020, 94, e1512-e1524.	1.5	53
180	Molecular Pathogenesis and Interventional Strategies for Alzheimerâ€™s Disease: Promises and Pitfalls. ACS Pharmacology and Translational Science, 2020, 3, 472-488.	2.5	21
181	Immunoadsorption for Treatment of Patients with Suspected Alzheimer Dementia and Agonistic Autoantibodies against Alpha1a-Adrenoceptorâ€”Rationale and Design of the IMAD Pilot Study. Journal of Clinical Medicine, 2020, 9, 1919.	1.0	4
182	The Hypothesis That Refuses to Die. , 2020, , 95-104.		0
183	New BACE1 Chimeric Peptide InhibitorsÂSelectively Prevent AÎ²PP-Î² Cleavage Decreasing Amyloid-Î² Production and Accumulation in Alzheimerâ€™s Disease Models. Journal of Alzheimer's Disease, 2020, 76, 1317-1337.	1.2	6

#	Article	IF	Citations
185	The Shaky Six and the â€œSecond Realityâ€• , 2020, , 1-10.		0
186	Pieces of a Puzzle?. , 2020, , 11-24.		0
187	Disease â€œRedefinitionâ€• A Tough Pill to Swallow. , 2020, , 25-32.		0
188	Disease Subtypes: The Promise and the Fallacy. , 2020, , 33-40.		2
189	Protein Paradox. , 2020, , 41-56.		0
190	The Fault in Our Models. , 2020, , 57-70.		0
191	Biomarkers: The Promise and the Fallacy. , 2020, , 71-80.		0
192	Lessons from Oncology. , 2020, , 81-86.		0
193	Symptomatic vs. Disease-Modifying Therapies. , 2020, , 87-94.		3
194	Our Living Dissonance. , 2020, , 105-110.		0
195	The Scientific and Lay Narratives. , 2020, , 111-124.		0
196	Challenges Viewed from Afar. , 2020, , 125-132.		0
197	The Moonshot: Population-Based Studies of Aging. , 2020, , 133-138.		0
198	Predictions for the 2020s and Beyond. , 2020, , 139-147.		0
199	Note Added at Press Time â€“ Reviving LOF. , 2020, , 150-150.		0
202	Reduction of Amyloid in the Brain and Retina After Treatment With IVIG for Mild Cognitive Impairment. American Journal of Alzheimer's Disease and Other Dementias, 2020, 35, 153331751989980.	0.9	9
203	Development of the clinical candidate PBD-C06, a humanized pGlu3-AÎ²-specific antibody against Alzheimerâ€™s disease with reduced complement activation. Scientific Reports, 2020, 10, 3294.	1.6	17
204	Pathogenic AÎ² generation in familial Alzheimerâ€™s disease: novel mechanistic insights and therapeutic implications. Current Opinion in Neurobiology, 2020, 61, 73-81.	2.0	22

#	Article	IF	Citations
205	Using practice effects for targeted trials or sub-group analysis in Alzheimerâ€™s disease: How practice effects predict change over time. PLoS ONE, 2020, 15, e0228064.	1.1	9
206	Sex and gender differences in Alzheimerâ€™s disease: current challenges and implications for clinical practice. European Journal of Neurology, 2020, 27, 928-943.	1.7	81
207	Is tau in the absence of amyloid on the Alzheimerâ€™s continuum?: A study of discordant PET positivity. Brain Communications, 2020, 2, fcz046.	1.5	53
208	Disease Modification in Alzheimerâ€™s Disease: Current Thinking. Therapeutic Innovation and Regulatory Science, 2020, 54, 396-403.	0.8	12
209	New Insights Into the Pathogenesis of Alzheimer's Disease. Frontiers in Neurology, 2019, 10, 1312.	1.1	194
210	Clarifying the Relationship Between Benzodiazepines and Dementia. Journal of the American Medical Directors Association, 2020, 21, 143-145.	1.2	6
211	Neurogranin as a cognitive biomarker in cerebrospinal fluid and blood exosomes for Alzheimerâ€™s disease and mild cognitive impairment. Translational Psychiatry, 2020, 10, 125.	2.4	48
212	Fish oil protects the bloodâ€“brain barrier integrity in a mouse model of Alzheimerâ€™s disease. Chinese Medicine, 2020, 15, 29.	1.6	14
213	Pharmaceutical applications of organofluorine compounds. , 2020, , 133-214.		0
214	Leveraging preclinical models for the development of Alzheimer disease therapeutics. Nature Reviews Drug Discovery, 2020, 19, 447-462.	21.5	73
215	What works and what does not work in Alzheimerâ€™s disease? From interventions on risk factors to antiâ€amyloid trials. Journal of Neurochemistry, 2020, 155, 120-136.	2.1	26
216	Resveratrol Derivatives as Potential Treatments for Alzheimerâ€™s and Parkinsonâ€™s Disease. Frontiers in Aging Neuroscience, 2020, 12, 103.	1.7	79
217	Learning from the Past: A Review of Clinical Trials Targeting Amyloid, Tau and Neuroinflammation in Alzheimerâ€™s Disease. Current Alzheimer Research, 2020, 17, 112-125.	0.7	40
218	Passive antiamyloid immunotherapy for Alzheimer's disease. Current Opinion in Psychiatry, 2020, 33, 284-291.	3.1	40
219	Clinical Trials in Alzheimerâ€™s Disease: A Hurdle in the Path of Remedy. International Journal of Alzheimer's Disease, 2020, 2020, 1-13.	1.1	62
220	Quantitative amyloid PET in Alzheimer's disease: the AMYPAD prognostic and natural history study. Alzheimer's and Dementia, 2020, 16, 750-758.	0.4	29
221	Hebbian and Homeostatic Synaptic Plasticityâ€”Do Alterations of One Reflect Enhancement of the Other?. Frontiers in Cellular Neuroscience, 2020, 14, 50.	1.8	27
222	Pharmacotherapy of Alzheimerâ€™s Disease: Seeking Clarity in a Time of Uncertainty. Frontiers in Pharmacology, 2020, 11, 261.	1.6	48

#	Article	IF	Citations
223	The Î²-Secretase BACE1 in Alzheimerâ€™s Disease. Biological Psychiatry, 2021, 89, 745-756.	0.7	336
224	Physical exercise protocols in animal models of Alzheimerâ€™s disease: a systematic review. Metabolic Brain Disease, 2021, 36, 85-95.	1.4	26
225	Alzheimer Disease Pathogenesis: The Role of Autoimmunity. journal of applied laboratory medicine, The, 2021, 6, 756-764.	0.6	19
226	Clinical trials of promising apoptosis modulating drugs. , 2021, , 329-391.		1
227	Î²-amyloid: The known unknowns. Ageing Research Reviews, 2021, 65, 101212.	5.0	27
228	Transformative Network Modeling of Multi-omics Data Reveals Detailed Circuits, Key Regulators, and Potential Therapeutics for Alzheimerâ€™s Disease. Neuron, 2021, 109, 257-272.e14.	3.8	108
229	Protection against Alzheimer's disease by luteolin: Role of brain glucose regulation, antiâ€inflammatory activity, and the gut microbiotaâ€liverâ€brain axis. BioFactors, 2021, 47, 218-231.	2.6	69
230	Novel Targets for Alzheimer's Disease: A View Beyond Amyloid. Annual Review of Medicine, 2021, 72, 15-28.	5.0	22
231	Amyloid and APOE Status of Screened Subjects in the Elenbecestat MissionAD Phase 3 Program. journal of prevention of Alzheimer's disease, The, 2021, 8, 1-6.	1.5	8
232	Axonal regeneration and sprouting as a potential therapeutic target for nervous system disorders. Neural Regeneration Research, 2021, 16, 1901.	1.6	23
233	Pattern and degree of individual brain atrophy predicts dementia onset in dominantly inherited Alzheimer's disease. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2021, 13, e12197.	1.2	4
234	Spatiotemporal processing of neural cell adhesion molecules 1 and 2 by BACE1 inÂvivo. Journal of Biological Chemistry, 2021, 296, 100372.	1.6	13
235	OUP accepted manuscript. Database: the Journal of Biological Databases and Curation, 2021, 2021, .	1.4	0
236	Lanabecestat: Neuroimaging results in early symptomatic Alzheimer's disease. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2021, 7, e12123.	1.8	9
237	Retinal Optical Coherence Tomography Metrics Are Unchanged in Verubecestat Alzheimerâ€™s Disease Clinical Trial but Correlate with Baseline Regional Brain Atrophy. Journal of Alzheimer's Disease, 2021, 79, 275-287.	1.2	7
238	Role of Adaptive Immune and Impacts of Risk Factors on Adaptive Immune in Alzheimerâ€™s Disease: Are Immunotherapies Effective or Off-Target?. Neuroscientist, 2022, 28, 254-270.	2.6	9
239	Role of Retinal Amyloid-Î² in Neurodegenerative Diseases: Overlapping Mechanisms and Emerging Clinical Applications. International Journal of Molecular Sciences, 2021, 22, 2360.	1.8	26
241	Time between milestone events in the Alzheimer's disease amyloid cascade. NeuroImage, 2021, 227, 117676.	2.1	20

#	Article	IF	Citations
242	Identification of aplysinopsin as a blood-brain barrier permeable scaffold for anti-cholinesterase and anti-BACE-1 activity. Bioorganic Chemistry, 2021, 107, 104568.	2.0	12
243	Natural Products Targeting Amyloid Beta in Alzheimerâ€™s Disease. International Journal of Molecular Sciences, 2021, 22, 2341.	1.8	17
244	Patient-derived iPSCs, a reliable in vitro model for the investigation of Alzheimerâ€™s disease. Reviews in the Neurosciences, 2021, 32, 379-402.	1.4	5
245	Discovery of Atabecestat (JNJ-54861911): A Thiazine-Based Î²-Amyloid Precursor Protein Cleaving Enzyme 1 Inhibitor Advanced to the Phase 2b/3 EARLY Clinical Trial. Journal of Medicinal Chemistry, 2021, 64, 1873-1888.	2.9	30
246	New Trajectory of Clinical and Biomarker Changes in Sporadic Alzheimerâ€™s Disease. Cerebral Cortex, 2021, 31, 3363-3373.	1.6	4
247	Findings of Efficacy, Safety, and Biomarker Outcomes of Atabecestat in Preclinical Alzheimer Disease. JAMA Neurology, 2021, 78, 293.	4.5	57
248	A Pathophysiological and Pharmacological review on Alzheimerâ€™s disease: A Current Need. Biomedical and Pharmacology Journal, 2021, 14, 75-80.	0.2	1
249	Structure-Based Approaches to Improving Selectivity through Utilizing Explicit Water Molecules: Discovery of Selective Î²-Secretase (BACE1) Inhibitors over BACE2. Journal of Medicinal Chemistry, 2021, 64, 3075-3085.	2.9	11
250	The use of the cellular thermal shift assay for the detection of intracellular beta-site amyloid precursor protein cleaving enzyme-1 ligand binding. Molecular Biology Reports, 2021, 48, 2957-2962.	1.0	3
251	The PKR/P38/RIPK1 Signaling Pathway as a Therapeutic Target in Alzheimerâ€™s Disease. International Journal of Molecular Sciences, 2021, 22, 3136.	1.8	17
252	Donepezil Combined with DL-3-n-Butylphthalide Delays Cognitive Decline in Patients with Mild to Moderate Alzheimerâ€™s Disease: A Multicenter, Prospective Cohort Study. Journal of Alzheimer's Disease, 2021, 80, 673-681.	1.2	7
253	Accelerated longâ€term forgetting is a BACE1 inhibitorâ€reversible incipient cognitive phenotype in Alzheimerâ€™s disease model mice. Neuropsychopharmacology Reports, 2021, 41, 255-259.	1.1	5
254	Alzheimerâ€™s Dementia: The Emerging Role of Positron Emission Tomography. Neuroscientist, 2022, 28, 507-519.	2.6	8
255	African Americans Have Differences in CSF Soluble TREM2 and Associated Genetic Variants. Neurology: Genetics, 2021, 7, e571.	0.9	27
256	Mitochondrial Permeability Transition: A Pore Intertwines Brain Aging and Alzheimerâ€™s Disease. Cells, 2021, 10, 649.	1.8	27
257	Value-Generating Exploratory Trials in Neurodegenerative Dementias. Neurology, 2021, 96, 944-954.	1.5	14
258	Preclinical validation of a potent Î³-secretase modulator for Alzheimerâ€™s disease prevention. Journal of Experimental Medicine, 2021, 218, .	4.2	39
259	Enhancing GABAergic signaling ameliorates aberrant gamma oscillations of olfactory bulb in AD mouse models. Molecular Neurodegeneration, 2021, 16, 14.	4.4	34

#	Article	IF	Citations
260	Recent advances in pre-clinical diagnosis of Alzheimerâ€™s disease. Metabolic Brain Disease, 2021, , 1.	1.4	3
261	Balancing potency and basicity by incorporating fluoropyridine moieties: Discovery of a 1-amino-3,4-dihydro-2,6-naphthyridine BACE1 inhibitor that affords robust and sustained central AÎ² reduction. European Journal of Medicinal Chemistry, 2021, 216, 113270.	2.6	7
262	The Use, Standardization, and Interpretation of Brain Imaging Data in Clinical Trials of Neurodegenerative Disorders. Neurotherapeutics, 2021, 18, 686-708.	2.1	19
263	Strategies to reduce sample sizes in Alzheimerâ€™s disease primary and secondary prevention trials using longitudinal amyloid PET imaging. Alzheimer's Research and Therapy, 2021, 13, 82.	3.0	14
264	Alzheimerâ€™s disease and its treatment by different approaches: A review. European Journal of Medicinal Chemistry, 2021, 216, 113320.	2.6	199
265	Phase II (NAVIGATE-AD study) Results of LY3202626 Effects on Patients with Mild Alzheimerâ€™s Disease Dementia. Journal of Alzheimer's Disease Reports, 2021, 5, 321-336.	1.2	17
266	Shared Genetic Background Between Cerebrospinal Fluid Biomarkers and Risk for Alzheimerâ€™s Disease: A Two-Sample Mendelian Randomization Study. Journal of Alzheimer's Disease, 2021, 80, 1197-1207.	1.2	3
267	Fluid Biomarkers in Clinical Trials for Alzheimerâ€™s Disease: Current and Future Application. Journal of Alzheimer's Disease, 2021, 81, 19-32.	1.2	3
268	Systematic in silico analysis of clinically tested drugs for reducing amyloidâ€beta plaque accumulation in Alzheimer's disease. Alzheimer's and Dementia, 2021, 17, 1487-1498.	0.4	22
269	Mesenchymal Stem Cell-Derived Exosomes Ameliorate Alzheimerâ€™s Disease Pathology and Improve Cognitive Deficits. Biomedicines, 2021, 9, 594.	1.4	55
270	Effect of antiamyloid-Î² drugs on Alzheimerâ€™s disease: study protocol for a systematic review and meta-analysis. BMJ Open, 2021, 11, e048453.	0.8	0
271	Study on Mechanism of Ginkgo biloba L. Leaves for the Treatment of Neurodegenerative Diseases Based on Network Pharmacology. Neurochemical Research, 2021, 46, 1881-1894.	1.6	10
272	Effects of concentrated ambient ultrafine particulate matter on hallmarks of Alzheimerâ€™s disease in the 3xTgAD mouse model. NeuroToxicology, 2021, 84, 172-183.	1.4	15
273	Recent Progress in the Drug Development for the Treatment of Alzheimerâ€™s Disease Especially on Inhibition of Amyloid-peptide Aggregation. Mini-Reviews in Medicinal Chemistry, 2021, 21, 969-990.	1.1	6
274	Insulin Resistance as a Common Link Between Current Alzheimerâ€™s Disease Hypotheses. Journal of Alzheimer's Disease, 2021, 82, 71-105.	1.2	21
275	Cognitive Go/No-Go decision-making criteria in Alzheimerâ€™s disease drug development. Drug Discovery Today, 2021, 26, 1330-1336.	3.2	3
276	Ganoderic Acid A Promotes Amyloid-Î² Clearance (In Vitro) and Ameliorates Cognitive Deficiency in Alzheimerâ€™s Disease (Mouse Model) Through Autophagy Induced by Activating Axl. International Journal of Molecular Sciences, 2021, 22, 5559.	1.8	22
277	Neuroprotective Natural Products for Alzheimerâ€™s Disease. Cells, 2021, 10, 1309.	1.8	90

#	Article	IF	Citations
278	Alzheimerâ€™s Disease Animal Models: Elucidation of Biomarkers and Therapeutic Approaches for Cognitive Impairment. International Journal of Molecular Sciences, 2021, 22, 5549.	1.8	20
279	¹¹C-PiB and¹²⁴I-Antibody PET Provide Differing Estimates of Brain Amyloid-Î² After Therapeutic Intervention. Journal of Nuclear Medicine, 2022, 63, 302-309.	2.8	19
280	Common variants in Alzheimerâ€™s disease and risk stratification by polygenic risk scores. Nature Communications, 2021, 12, 3417.	5.8	140
281	Emerging insights into the role of albumin with plasma exchange in Alzheimerâ€™s disease management. Transfusion and Apheresis Science, 2021, 60, 103164.	0.5	12
282	BACE1 controls synaptic function through modulating release of synaptic vesicles. Molecular Psychiatry, 2021, 26, 6394-6410.	4.1	20
283	Lifelong chronic psychosocial stress induces a proteomic signature of Alzheimer's disease in wildtype mice. European Journal of Neuroscience, 2022, 55, 2971-2985.	1.2	6
284	Amyloid Î² and Amyloid Precursor Protein Synergistically Suppress Large-Conductance Calcium-Activated Potassium Channel in Cortical Neurons. Frontiers in Aging Neuroscience, 2021, 13, 660319.	1.7	8
285	Association of plasma P-tau181 with memory decline in non-demented adults. Brain Communications, 2021, 3, fcab136.	1.5	33
286	An Overview of Î²-Amyloid Cleaving Enzyme 1 (BACE1) in Alzheimer's Disease Therapy: Elucidating its Exosite-Binding Antibody and Allosteric Inhibitor. Current Medicinal Chemistry, 2022, 29, 114-135.	1.2	4
287	Synthesis and evaluation of multi-target-directed ligands with BACE-1 inhibitory and Nrf2 agonist activities as potential agents against Alzheimerâ€™s disease. European Journal of Medicinal Chemistry, 2021, 219, 113441.	2.6	20
288	The informed road map to prevention of Alzheimer Disease: A call to arms. Molecular Neurodegeneration, 2021, 16, 49.	4.4	43
289	AÎ·Î± and AÎ·Î² peptides impair LTP ex vivo within the low nanomolar range and impact neuronal activity in vivo. Alzheimer's Research and Therapy, 2021, 13, 125.	3.0	7
290	The Geriatrician, the Primary Care Physician, Aducanumab and the FDA Decision: From Frustration to New Hope. Journal of Nutrition, Health and Aging, 2021, 25, 821-823.	1.5	8
291	Post-translational modifications: Regulators of neurodegenerative proteinopathies. Ageing Research Reviews, 2021, 68, 101336.	5.0	45
292	BACE inhibitor treatment of mice induces hyperactivity in a Seizure-related gene 6 family dependent manner without altering learning and memory. Scientific Reports, 2021, 11, 15084.	1.6	3
293	Defective Autophagy and Mitophagy in Alzheimerâ€™s Disease: Mechanisms and Translational Implications. Molecular Neurobiology, 2021, 58, 5289-5302.	1.9	17
294	Novel Therapeutic Approaches for Alzheimerâ€™s Disease: An Updated Review. International Journal of Molecular Sciences, 2021, 22, 8208.	1.8	62
295	On the design of early-phase Alzheimerâ€™s disease clinical trials with cerebrospinal fluid tau outcomes. Clinical Trials, 2021, 18, 714-723.	0.7	3

#	Article	IF	Citations
296	Novel bioengineered MBenes for the treatment of Alzheimer's disease: An in-Sillico study. Journal of Biomolecular Structure and Dynamics, 2022, 40, 12268-12276.	2.0	4
297	Novel Biomarkers of Alzheimer's Disease: Based Upon N-methyl-D-aspartate Receptor Hypoactivation and Oxidative Stress. Clinical Psychopharmacology and Neuroscience, 2021, 19, 423-433.	0.9	11
298	Alzheimer's Disease and Î²-secretase Inhibition: An Update with a Focus on Computer-aided Inhibitor Design. Current Drug Targets, 2022, 23, 266-285.	1.0	11
299	Methodological Issues in Randomized Clinical Trials for Prodromal Alzheimer's and Parkinson's Disease. Frontiers in Neurology, 2021, 12, 694329.	1.1	8
300	Casein Kinase 2 dependent phosphorylation of eIF4B regulates BACE1 expression in Alzheimerâ€™s disease. Cell Death and Disease, 2021, 12, 769.	2.7	8
301	Soluble Amyloid-Î² Consumption in Alzheimerâ€™s Disease. Journal of Alzheimer's Disease, 2021, 82, 1403-1415.	1.2	31
302	Combined association of cognitive impairment and poor oral health on mortality risk in older adults: Results from the NHANES with 15 years of followâ€up. Journal of Periodontology, 2022, 93, 888-900.	1.7	13
303	Overexpression of wild-type human amyloid precursor protein alters GABAergic transmission. Scientific Reports, 2021, 11, 17600.	1.6	11
304	Effect of High Cholesterol Regulation of LRP1 and RAGE on AÎ² Transport Across the Blood-Brain Barrier in Alzheimerâ€™s Disease. Current Alzheimer Research, 2021, 18, 428-442.	0.7	19
305	Pregabalin Treatment does not Affect Amyloid Pathology in 5XFAD Mice. Current Alzheimer Research, 2021, 18, 283-297.	0.7	3
306	Efficacy of preclinical pharmacological interventions against alterations of neuronal network oscillations in Alzheimer's disease: A systematic review. Experimental Neurology, 2021, 343, 113743.	2.0	7
307	Proportion of Women and Reporting of Outcomes by Sex in Clinical Trials for Alzheimer Disease. JAMA Network Open, 2021, 4, e2124124.	2.8	30
308	Discovery of Extremely Selective Fused Pyridine-Derived Î²-Site Amyloid Precursor Protein-Cleaving Enzyme (BACE1) Inhibitors with High In Vivo Efficacy through 10s Loop Interactions. Journal of Medicinal Chemistry, 2021, 64, 14165-14174.	2.9	4
309	The case for low-level BACE1 inhibition for the prevention of Alzheimer disease. Nature Reviews Neurology, 2021, 17, 703-714.	4.9	65
310	Therapeutic Efficacy of Plasmalogens for Alzheimerâ€™s Disease, Mild Cognitive Impairment, and Parkinsonâ€™s Disease in Conjunction with a New Hypothesis for the Etiology of Alzheimerâ€™s Disease. Advances in Experimental Medicine and Biology, 2020, 1299, 195-212.	0.8	15
311	Stress and Alzheimerâ€™s disease: A senescence link?. Neuroscience and Biobehavioral Reviews, 2020, 115, 285-298.	2.9	29
318	The Neuropsychiatric Inventory: Development and Applications. Journal of Geriatric Psychiatry and Neurology, 2020, 33, 73-84.	1.2	83
319	Early diagnosis and treatment of Alzheimerâ€™s disease: new definitions and challenges. Revista Brasileira De Psiquiatria, 2020, 42, 431-441.	0.9	42

#	Article	IF	Citations
320	Alzheimerâ€™s disease as a multistage process: an analysis from a population-based cohort study. Aging, 2019, 11, 1163-1176.	1.4	12
321	The Main Targets Involved in Neuroprotection for the Treatment of Alzheimerâ€™s Disease and Parkinson Disease. Current Pharmaceutical Design, 2020, 26, 509-516.	0.9	9
322	A Chronological Review of Potential Disease-Modifying Therapeutic Strategies for Alzheimer's Disease. Current Pharmaceutical Design, 2020, 26, 1286-1299.	0.9	12
323	Therapeutic Strategies Targeting Amyloid-Î² in Alzheimerâ€™s Disease. Current Alzheimer Research, 2019, 16, 418-452.	0.7	88
324	Scopolamine, a Toxin-Induced Experimental Model, Used for Research in Alzheimerâ€™s Disease. CNS and Neurological Disorders - Drug Targets, 2020, 19, 85-93.	0.8	49
325	Amyloid-Negative Dementia in the Elderly is Associated with High Accumulation of Tau in the Temporal Lobes. Open Biomedical Engineering Journal, 2019, 13, 55-66.	0.7	1
326	Alzheimerâ€™s Disease is Driven by Intraneuronally Retained Beta-Amyloid Produced in the AD-Specific, Î²APP-Independent Pathway: Current Perspective and Experimental Models for Tomorrow. Annals of Integrative Molecular Medicine, 2019, 2, 90-114.	0.0	14
327	Alzheimerâ€™s Disease Prevention and Treatment: Case for Optimism. Annals of Integrative Molecular Medicine, 2019, 2, 0115-0130.	0.0	5
328	Hydrogels for neuroprotection and functional rewiring: a new era for brain engineering. Neural Regeneration Research, 2020, 15, 783.	1.6	25
329	Intranasal Administration of Conditioned Medium from Cultured Mesenchymal Stem Cells Improves Cognitive Impairment in Olfactory Bulbectomized Mice. Advances in Alzheimer's Disease, 2020, 09, 47-56.	0.3	1
330	Cortical tau deposition follows patterns of entorhinal functional connectivity in aging. ELife, 2019, 8, .	2.8	83
332	Past, present and future of therapeutic strategies against amyloid-Î² peptides in Alzheimerâ€™s disease: a systematic review. Ageing Research Reviews, 2021, 72, 101496.	5.0	131
333	Discovery of Umibecestat (CNP520): A Potent, Selective, and Efficacious Î²-Secretase (BACE1) Inhibitor for the Prevention of Alzheimerâ€™s Disease. Journal of Medicinal Chemistry, 2021, 64, 15262-15279.	2.9	14
334	Structureâ€“activity relationship study of hydroxyethylamine isostere and P1â€² site structure of peptide mimetic BACE1 inhibitors. Bioorganic and Medicinal Chemistry, 2021, 50, 116459.	1.4	2
335	Amyloid peptide exerts a rapid induction of Dicer1 protein in neuron via reducing phosphorylation. Neurochemistry International, 2021, 151, 105210.	1.9	1
336	Discovery of PT-65 as a highly potent and selective Proteolysis-targeting chimera degrader of GSK3 for treating Alzheimer's disease. European Journal of Medicinal Chemistry, 2021, 226, 113889.	2.6	13
338	Alzheimerâ€™s Disease - Clinical Trials. Materials and Methods, 0, 8, .	0.0	0
339	Neuro-inflammation dans les maladies neurologiques. RÃ1e des probiotiques. Phytotherapie, 2018, 16, 326-335.	0.1	0

#	Article	IF	Citations
340	Geriatrics update 2018: Challenges in mental health, mobility, and postdischarge care. Cleveland Clinic Journal of Medicine, 2018, 85, 953-958.	0.6	1
341	A Novel Cell-based Î²-secretase Enzymatic Assay for Alzheimerâ€™s Disease. Current Alzheimer Research, 2019, 16, 128-134.	0.7	0
342	News from Mars: Two-Tier Paradox, Intracellular PCR, Chimeric Junction Shift, Dark Matter mRNA and Other Remarkable Features of Mammalian RNA-Dependent mRNA Amplification. Implications for Alzheimerâ€™s Disease, RNA-Based Vaccines and mRNA Therapeutics. Annals of Integrative Molecular Medicine, 2019, 2, 0131-0173.	0.0	4
343	Safety and tolerability of GRF6019 in mildâ€toâ€moderate Alzheimer's disease dementia. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2020, 6, e12115.	1.8	6
348	RhoA/Rock2/Limk1/cofilin1 pathway is involved in attenuation of neuronal dendritic spine loss by paeonol in the frontal cortex of D-galactose and aluminum-induced Alzheimerâ€™s disease-like rat model. Acta Neurobiologiae Experimentalis, 2020, 80, 225-244.	0.4	13
350	Comparative functional genomic analysis of Alzheimerâ€™s affected and naturally aging brains. PeerJ, 2020, 8, e8682.	0.9	3
351	Facteurs de risque de la maladie dâ€™Alzheimer et des maladies apparentÃ©esÂ: approche parcours de vie. Bulletin De L'Academie Nationale De Medecine, 2020, 204, 217-223.	0.0	1
352	Applying C. elegans to the Industrial Drug Discovery Process to Slow Aging. Frontiers in Aging, 2021, 2, .	1.2	3
353	Neuropsychological, neuropsychiatric, and qualityâ€ofâ€life assessments in Alzheimer's disease patients treated with plasma exchange with albumin replacement from the randomized AMBAR study. Alzheimer's and Dementia, 2022, 18, 1314-1324.	0.4	17
354	Pharmacological inhibition of BACE1 suppresses glioblastoma growth by stimulating macrophage phagocytosis of tumor cells. Nature Cancer, 2021, 2, 1136-1151.	5.7	41
356	Design and discovery of C2-fluoroalkyl iminothiazine dioxides as BACE inhibitors. Bioorganic and Medicinal Chemistry Letters, 2022, 56, 128463.	1.0	0
357	Inhibition of BACE1 and amyloid Î² aggregation by polyketide from Streptomyces sp.. Chemical Biology and Drug Design, 2022, 99, 264-276.	1.5	0
358	Nutrition senolytics - illusion or reality for cognitive ageing?. Current Opinion in Clinical Nutrition and Metabolic Care, 2021, Publish Ahead of Print, 7-28.	1.3	2
359	Anti-Inflammatory Agents: An Approach to Prevent Cognitive Decline in Alzheimerâ€™s Disease. Journal of Alzheimer's Disease, 2022, 85, 457-472.	1.2	6
360	Neuropathology of a patient with Alzheimer disease treated with low doses of verubecestat. Neuropathology and Applied Neurobiology, 2022, 48, .	1.8	1
361	Handling Intercurrent Events Through Hypothetical Strategy in Delayed-Start Designs. Statistics in Biopharmaceutical Research, 0, , 1-19.	0.6	0
362	Macrocyclic BACE1 inhibitors with hydrophobic cross-linked structures: Optimization of ring size and ring structure. Bioorganic and Medicinal Chemistry, 2021, 52, 116517.	1.4	1
363	BACE1: A Key Regulator in Alzheimerâ€™s Disease Progression and Current Development of its Inhibitors. Current Neuropharmacology, 2022, 20, 1174-1193.	1.4	12

#	Article	IF	Citations
365	Sulforaphane ameliorates amyloid-Î²-induced inflammatory injury by suppressing the PARP1/SIRT1 pathway in retinal pigment epithelial cells. Bioengineered, 2022, 13, 7079-7089.	1.4	8
366	Mechanistic and therapeutic implications of EphAâ€4 receptor tyrosine kinase in the pathogenesis of Alzheimer's disease. European Journal of Neuroscience, 2022, 56, 5532-5546.	1.2	8
367	Review of evidence implicating the plasminogen activator system in blood-brain barrier dysfunction associated with Alzheimerâ€™s disease. , 2022, 2, .		3
368	The role of brain-derived neurotrophic factor and the neurotrophin receptor p75NTR in age-related brain atrophy and the transition to Alzheimerâ€™s disease. Reviews in the Neurosciences, 2022, 33, 515-529.	1.4	7
369	Regulation of microRNAs in AlzheimerÂ´s disease, type 2 diabetes, and aerobic exercise training. Metabolic Brain Disease, 2022, 37, 559-580.	1.4	4
370	Robust Pharmacodynamic Effect of LY3202626, a Central Nervous System Penetrant, Low Dose BACE1 Inhibitor, in Humans and Nonclinical Species. Journal of Alzheimer's Disease Reports, 2022, 6, 1-15.	1.2	4
371	Role of prolineâ€rich tyrosine kinase 2 (Pyk2) in the pathogenesis of Alzheimer's disease. European Journal of Neuroscience, 2022, 56, 5442-5452.	1.2	2
372	A short peptide from sAPPÎ± binding to BACE1-APP action site rescues Alzheimer-like pathology. Neuroscience Letters, 2022, 770, 136397.	1.0	1
373	Mechanistic and therapeutic role of Drp1 in the pathogenesis of Alzheimer's disease. European Journal of Neuroscience, 2022, 56, 5516-5531.	1.2	13
374	Direct neuronal reprogramming: Fast forward from new concepts toward therapeutic approaches. Neuron, 2022, 110, 366-393.	3.8	45
375	Physiology and pharmacology of amyloid precursor protein. , 2022, 235, 108122.		33
376	BACE1: More than just a Î²â€secretase. Obesity Reviews, 2022, 23, e13430.	3.1	32
377	Hope or hype? Aducanumab as a magic bullet for Alzheimerâ€™s disease. BIO Integration, 2022, 3, .	0.9	3
379	New Perspectives for Treatment in Alzheimerâ€™s Disease. , 2022, , 199-225.		0
380	Early termination of pivotal trials in Alzheimer's diseaseâ€”Preserving optimal value for participants and science. Alzheimer's and Dementia, 2022, , .	0.4	1
381	Effects of microRNA-298 on APP and BACE1 translation differ according to cell type and 3â€²-UTR variation. Scientific Reports, 2022, 12, 3074.	1.6	8
383	The amyloid hypothesis in Alzheimer disease: new insights from new therapeutics. Nature Reviews Drug Discovery, 2022, 21, 306-318.	21.5	273
384	Neurodegenerative Diseases: The Value of Early Predictive End Points. Clinical Pharmacology and Therapeutics, 2022, 111, 835-839.	2.3	3

#	Article	IF	Citations
386	Neurotechnological Approaches to the Diagnosis and Treatment of Alzheimerâ€™s Disease. Frontiers in Neuroscience, 2022, 16, 854992.	1.4	12
387	Alzheimerâ€™s Disease: Key Insights from Two Decades of Clinical Trial Failures. Journal of Alzheimer's Disease, 2022, 87, 83-100.	1.2	56
388	KIBRA regulates amyloid Î² metabolism by controlling extracellular vesicles secretion. EBioMedicine, 2022, 78, 103980.	2.7	1
389	A Model-Based Approach to Bridging Plasma and Dried Blood Spot Concentration Data for Phase 3 Verubecestat Trials. AAPS Journal, 2022, 24, 53.	2.2	4
390	An Investigation of Instability in Dried Blood Spot Samples for Pharmacokinetic Sampling in Phase 3 Trials of Verubecestat. AAPS Journal, 2022, 24, 52.	2.2	2
391	Versatile nanomaterials for Alzheimer's disease: Pathogenesis inspired disease-modifying therapy. Journal of Controlled Release, 2022, 345, 38-61.	4.8	11
392	Amyloid Beta Dynamics in Biological Fluidsâ€”Therapeutic Impact. Journal of Clinical Medicine, 2021, 10, 5986.	1.0	1
393	The Î²-Secretase Substrate Seizure 6â€“Like Protein (SEZ6L) Controls Motor Functions in Mice. Molecular Neurobiology, 2022, 59, 1183-1198.	1.9	3
394	Association of CSF AÎ² ₃₈ Levels With Risk of Alzheimer Diseaseâ€“Related Decline. Neurology, 2022, 98, .	1.5	16
396	PTPRD and DCC Are Novel BACE1 Substrates Differentially Expressed in Alzheimerâ€™s Disease: A Data Mining and Bioinformatics Study. International Journal of Molecular Sciences, 2022, 23, 4568.	1.8	4
410	Prediction of Cognitive Decline for Enrichment of Alzheimerâ€™s Disease Clinical Trials. journal of prevention of Alzheimer's disease, The, 0, , 1.	1.5	2
411	Shared pathophysiology: Understanding stroke and Alzheimerâ€™s disease. Clinical Neurology and Neurosurgery, 2022, 218, 107306.	0.6	9
412	The future of stem cell therapies of Alzheimerâ€™s disease. Ageing Research Reviews, 2022, 80, 101655.	5.0	5
414	Physiological Roles of Monomeric Amyloid-Î² and Implications for Alzheimerâ€™s Disease Therapeutics. Experimental Neurobiology, 2022, 31, 65-88.	0.7	21
415	Mouse Models of Alzheimerâ€™s Disease. Frontiers in Molecular Neuroscience, 0, 15, .	1.4	50
416	Neuropharmacology of Organoselenium Compounds in Mental Disorders and Degenerative Diseases. Current Medicinal Chemistry, 2023, 30, 2357-2395.	1.2	12
417	Prophylactic evaluation of verubecestat on diseaseâ€•and symptomâ€•modifying effects in 5XFAD mice. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2022, 8, .	1.8	5
418	The Amyloid Cascade Hypothesis 2.0: On the Possibility of Once-in-a-Lifetime-Only Treatment for Prevention of Alzheimerâ€™s Disease and for Its Potential Cure at Symptomatic Stages. Journal of Alzheimer's Disease Reports, 2022, 6, 369-399.	1.2	6

#	Article	IF	Citations
419	Antiamyloid therapy of Alzheimerâ€™s disease: origins, current state and prospects of development. Neurology Bulletin, 2022, LIV, 56-68.	0.0	0
420	Pharmacotherapy for Alzheimerâ€™s disease: whatâ€™s new on the horizon?. Expert Opinion on Pharmacotherapy, 0, , 1-19.	0.9	1
421	Resveratrol ameliorates learning and memory impairments induced by bilateral hippocampal injection of streptozotocin in mice. Neurochemistry International, 2022, 159, 105385.	1.9	8
422	Hallmarks of neurodegenerative disease: A systems pharmacology perspective. CPT: Pharmacometrics and Systems Pharmacology, 2022, 11, 1399-1429.	1.3	15
423	Exploratory analyses of clinical trial data used for health technology assessments: a retrospective evaluation. BMJ Open, 2022, 12, e058146.	0.8	0
424	Evaluation of 18F-flutemetamol amyloid PET image analysis parameters on the effect of verubecestat on brain amlyoid load in Alzheimerâ€™s disease. Molecular Imaging and Biology, 2022, 24, 862-873.	1.3	2
425	Treatment of Alzheimer’s disease by promoting the aggregation of small β-amyloid peptides. Scientia Sinica Vitae, 2022, 52, 1184-1191.	0.1	2
426	Diagnostic and therapeutic potential of protease inhibition. Molecular Aspects of Medicine, 2022, 88, 101144.	2.7	7
427	Analysis on the Pathogenesis and Nursing of Alzheimerâ€™s Disease. SHS Web of Conferences, 2022, 144, 01013.	0.1	1
428	Patents and applications of N-sulfonated N-heterocycles. , 2022, , 447-496.		2
429	Based on molecular structures: Amyloid-Î² generation, clearance, toxicity and therapeutic strategies. Frontiers in Molecular Neuroscience, 0, 15, .	1.4	6
430	Stable cerebrospinal fluid neurogranin and Î²-site amyloid precursor protein cleaving enzyme 1 levels differentiate predementia Alzheimerâ€™s disease patients. Brain Communications, 2022, 4, .	1.5	1
431	Clinical relevance of biomarkers, new therapeutic approaches, and role of post-translational modifications in the pathogenesis of Alzheimerâ€™s disease. Frontiers in Aging Neuroscience, 0, 14, .	1.7	4
432	Associations of Naturally Occurring Antibodies to Presenilin-1 with Brain Amyloid-Î² Load and Cognitive Impairment in Alzheimerâ€™s Disease. Journal of Alzheimer's Disease, 2022, , 1-8.	1.2	3
433	Comprehensive characterization of elevated tau PET signal in the absence of amyloid-beta. Brain Communications, 2022, 4, .	1.5	5
434	A Novel Strategy for Alzheimerâ€™s Disease Based on the Regulatory Effect of Amyloid-Î² on Gut Flora. Journal of Alzheimer's Disease, 2022, , 1-13.	1.2	2
435	Experimental evidence for temporal uncoupling of brain AÎ² deposition and neurodegenerative sequelae. Nature Communications, 2022, 13, .	5.8	6
436	Physiological Roles of Î²-amyloid in Regulating Synaptic Function: Implications for AD Pathophysiology. Neuroscience Bulletin, 2023, 39, 1289-1308.	1.5	13

#	Article	IF	Citations
437	Retrospective Bayesian Evidence of Null Effect in Two Decades of Alzheimerâ€™s Disease Clinical Trials. Journal of Alzheimer's Disease, 2023, 91, 531-535.	1.2	3
438	The Strategies for Treating â€œAlzheimerâ€™s Diseaseâ€• Insulin Signaling May Be a Feasible Target. Current Issues in Molecular Biology, 2022, 44, 6172-6188.	1.0	5
439	BACE1 Inhibitors for Alzheimerâ€™s Disease: The Past, Present and Any Future?. Molecules, 2022, 27, 8823.	1.7	12
440	Role of monomeric amyloid-Î² in cognitive performance in Alzheimer's disease: Insights from clinical trials with secretase inhibitors and monoclonal antibodies. Pharmacological Research, 2023, 187, 106631.	3.1	22
441	Experimental approaches for altering the expression of Abetaâ€degrading enzymes. Journal of Neurochemistry, 2023, 164, 725-763.	2.1	4
442	Exploration of the potential neuroprotective compounds targeting GluN1-GluN2B NMDA receptors. Journal of Biomolecular Structure and Dynamics, 2023, 41, 10900-10908.	2.0	1
443	Neuronal deletion of nSMase2 reduces the production of AÎ² and directly protects neurons. Neurobiology of Disease, 2023, 177, 105987.	2.1	0
444	Drug Discovery to Drug Development of BACE1 Inhibitor as Antialzheimerâ€™s: A Review. Current Topics in Medicinal Chemistry, 2023, 23, 77-97.	1.0	3
445	Advances in Alzheimerâ€™s diseaseâ€™s pharmacological treatment. Frontiers in Pharmacology, 0, 14, .	1.6	10
446	The Amyloid Cascade Hypothesis 2.0: Generalization of the Concept. Journal of Alzheimer's Disease Reports, 2023, 7, 21-35.	1.2	4
447	Role of microbial dysbiosis in the pathogenesis of Alzheimer's disease. Neuropharmacology, 2023, 229, 109478.	2.0	10
448	Kaempferol as a therapeutic agent in Alzheimerâ€™s disease: Evidence from preclinical studies. Ageing Research Reviews, 2023, 87, 101910.	5.0	9
449	Photoinduced Vicinal 1,2-Difunctionalization of Olefins for the Synthesis of Alkyl Sulfonamides. Organic Letters, 2023, 25, 1014-1019.	2.4	9
450	Mechanisms of amyloid-Î²34 generation indicate a pivotal role for BACE1 in amyloid homeostasis. Scientific Reports, 2023, 13, .	1.6	1
451	Finding the falsification threshold of the toxic proteinopathy hypothesis in neurodegeneration. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2023, , 143-154.	1.0	6
452	Disease-modifying vs symptomatic treatments: Splitting over lumping. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2023, , 187-209.	1.0	5
453	The Alzheimerâ€™s disease-linked protease BACE1 modulates neuronal IL-6 signaling through shedding of the receptor gp130. Molecular Neurodegeneration, 2023, 18, .	4.4	4
454	Bilateral Hippocampal Volume Mediated the Relationship Between Plasma BACE1 Concentration and Memory Function in the Early Stage of Alzheimerâ€™s Disease: A Cross-Sectional Study. Journal of Alzheimer's Disease, 2023, 92, 1001-1013.	1.2	0

#	Article	IF	Citations
455	The effects of microglia-associated neuroinflammation on Alzheimerâ€™s disease. Frontiers in Immunology, 0, 14, .	2.2	20
456	The past and present of therapeutic strategy for Alzheimerâ€™s diseases: potential for stem cell therapy. Experimental Animals, 2023, 72, 285-293.	0.7	2
457	The neuroprotective effects of targeting key factors of neuronal cell death in neurodegenerative diseases: The role of ER stress, oxidative stress, and neuroinflammation. Frontiers in Cellular Neuroscience, 0, 17, .	1.8	14
458	Poor Translatability of Biomedical Research Using Animals â€" A Narrative Review. ATLA Alternatives To Laboratory Animals, 2023, 51, 102-135.	0.7	14
459	A comprehensive characterization of hippocampal feature ensemble serves as individualized brain signature for Alzheimerâ€™s disease: deep learning analysis in 3238 participants worldwide. European Radiology, 0, , .	2.3	2
460	Lecanamab Ushers in a New Era of Antiâ€Amyloid Therapy for Alzheimer's Disease. Annals of Neurology, 2023, 93, 877-880.	2.8	3
461	Accelerated Brain Volume Loss Caused by Antiâ€"Î²-Amyloid Drugs. Neurology, 2023, 100, .	1.5	53
462	New Insights into Alzheimerâ€™s Disease: Novel Pathogenesis, Drug Target and Delivery. Pharmaceutics, 2023, 15, 1133.	2.0	2
463	Five-mer peptides prevent short-term spatial memory deficits in Aβ25-35-induced Alzheimerâ€™s model mouse by suppressing Aβ25-35 aggregation and resolving its aggregate form. Alzheimer's Research and Therapy, 2023, 15, .	3.0	4
464	Vector enabled CRISPR gene editing â€" A revolutionary strategy for targeting the diversity of brain pathologies. Coordination Chemistry Reviews, 2023, 487, 215172.	9.5	0
465	Women and Alzheimer's disease. , 2023, , 273-305.		0
474	Charting the Next Road Map for CSF Biomarkers in Alzheimer's Disease and Related Dementias. Neurotherapeutics, 2023, 20, 955-974.	2.1	2
476	Cognitive Enhancers and Treatments for Alzheimerâ€™s Disease. , 2023, , 1-42.		0
487	Emerging diagnostics and therapeutics for Alzheimer disease. Nature Medicine, 2023, 29, 2187-2199.	15.2	20
505	Symptoms and conventional treatments of Alzheimer's disease. , 2024, , 213-234.		1